All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Outcomes of triple-class exposed/refractory disease in real-world care: What is the current SoC?

During the ASCO 2021 Annual Meeting, the Multiple Myeloma Hub spoke with Maria Victoria Mateos, University Hospital of Salamanca, Salamanca, ES. We asked, what are the outcomes of triple-class exposed/refractory disease in real-world care: What is the current SoC?

Outcomes of triple-class exposed/refractory disease in real-world care: What is the current SoC?

Mateos discusses the results from LocoMMotion (NCT04035226), the first prospective efficacy and safety study of real-life SOC in patients with relapsed/refractory multiple myeloma (RRMM). 

 

Share: